412 related articles for article (PubMed ID: 29260289)
1. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.
Doyle N; Varela A; Haile S; Guldberg R; Kostenuik PJ; Ominsky MS; Smith SY; Hattersley G
Osteoporos Int; 2018 Mar; 29(3):685-697. PubMed ID: 29260289
[TBL] [Abstract][Full Text] [Related]
2. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.
Varela A; Chouinard L; Lesage E; Smith SY; Hattersley G
J Bone Miner Res; 2017 Jan; 32(1):24-33. PubMed ID: 27748532
[TBL] [Abstract][Full Text] [Related]
3. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.
Bahar H; Gallacher K; Downall J; Nelson CA; Shomali M; Hattersley G
Calcif Tissue Int; 2016 Nov; 99(5):489-499. PubMed ID: 27395059
[TBL] [Abstract][Full Text] [Related]
4. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia.
Chandler H; Brooks DJ; Hattersley G; Bouxsein ML; Lanske B
Osteoporos Int; 2019 Aug; 30(8):1607-1616. PubMed ID: 31053927
[TBL] [Abstract][Full Text] [Related]
5. One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.
Varela A; Chouinard L; Lesage E; Guldberg R; Smith SY; Kostenuik PJ; Hattersley G
Bone; 2017 Feb; 95():143-150. PubMed ID: 27894941
[TBL] [Abstract][Full Text] [Related]
6. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption.
Chandler H; Lanske B; Varela A; Guillot M; Boyer M; Brown J; Pierce A; Ominsky M; Mitlak B; Baron R; Kostenuik P; Hattersley G
Bone; 2019 Mar; 120():148-155. PubMed ID: 30343166
[TBL] [Abstract][Full Text] [Related]
7. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis.
Besschetnova T; Brooks DJ; Hu D; Nagano K; Nustad J; Ominsky M; Mitlak B; Hattersley G; Bouxsein ML; Baron R; Lanske B
Bone; 2019 Jul; 124():148-157. PubMed ID: 31051317
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
[TBL] [Abstract][Full Text] [Related]
9. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody.
Kostenuik PJ; Smith SY; Jolette J; Schroeder J; Pyrah I; Ominsky MS
Bone; 2011 Aug; 49(2):151-61. PubMed ID: 21457806
[TBL] [Abstract][Full Text] [Related]
10. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
Ominsky MS; Stouch B; Schroeder J; Pyrah I; Stolina M; Smith SY; Kostenuik PJ
Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676
[TBL] [Abstract][Full Text] [Related]
11. Effects of 16-month treatment with the cathepsin K inhibitor ONO-5334 on bone markers, mineral density, strength and histomorphometry in ovariectomized cynomolgus monkeys.
Yamada H; Ochi Y; Mori H; Nishikawa S; Hashimoto Y; Nakanishi Y; Tanaka M; Bruce M; Deacon S; Kawabata K
Bone; 2016 May; 86():43-52. PubMed ID: 26921823
[TBL] [Abstract][Full Text] [Related]
12. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
[TBL] [Abstract][Full Text] [Related]
13. Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys.
Ominsky MS; Boyd SK; Varela A; Jolette J; Felx M; Doyle N; Mellal N; Smith SY; Locher K; Buntich S; Pyrah I; Boyce RW
J Bone Miner Res; 2017 Apr; 32(4):788-801. PubMed ID: 27865001
[TBL] [Abstract][Full Text] [Related]
14. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity.
Sato M; Westmore M; Ma YL; Schmidt A; Zeng QQ; Glass EV; Vahle J; Brommage R; Jerome CP; Turner CH
J Bone Miner Res; 2004 Apr; 19(4):623-9. PubMed ID: 15005850
[TBL] [Abstract][Full Text] [Related]
15. Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab.
Ominsky MS; Libanati C; Niu QT; Boyce RW; Kostenuik PJ; Wagman RB; Baron R; Dempster DW
J Bone Miner Res; 2015 Jul; 30(7):1280-9. PubMed ID: 25684625
[TBL] [Abstract][Full Text] [Related]
16. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.
Kostenuik PJ; Smith SY; Samadfam R; Jolette J; Zhou L; Ominsky MS
J Bone Miner Res; 2015 Apr; 30(4):657-69. PubMed ID: 25369992
[TBL] [Abstract][Full Text] [Related]
17. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
[TBL] [Abstract][Full Text] [Related]
19. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine.
Fox J; Miller MA; Newman MK; Turner CH; Recker RR; Smith SY
J Bone Miner Res; 2007 Feb; 22(2):260-73. PubMed ID: 17087625
[TBL] [Abstract][Full Text] [Related]
20. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Jerome CP; Burr DB; Van Bibber T; Hock JM; Brommage R
Bone; 2001 Feb; 28(2):150-9. PubMed ID: 11182372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
